Across TCGA pan-cancer cohorts, ZNF876P Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF876P data layer compared with 23 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ZNF876P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF876P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and SARC are the cancer types where ZNF876P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.599	0.924	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.619	.007	24	view →
SARC	OS	Median	All	0.156	0.767	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF876P tumor-vs-normal RNA expression · all ZNF876P data types